Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib for Prevention of Chemotherapy-Induced Bone Marrow Suppression in Advanced NSCLC
NCT06370416Phase 2Enrolling by invitation
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trilaciclib in non-small cell lung cancer (NSCLC), sponsored by Henan Cancer Hospital. Started Apr 2024; status: enrolling by invitation.
02
Drugs
trilaciclib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06370416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06370416.